JP2017538672A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017538672A5 JP2017538672A5 JP2017522532A JP2017522532A JP2017538672A5 JP 2017538672 A5 JP2017538672 A5 JP 2017538672A5 JP 2017522532 A JP2017522532 A JP 2017522532A JP 2017522532 A JP2017522532 A JP 2017522532A JP 2017538672 A5 JP2017538672 A5 JP 2017538672A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cmv
- amino acid
- acid sequence
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14189897 | 2014-10-22 | ||
| EP14189897.3 | 2014-10-22 | ||
| EP15184192.1 | 2015-09-08 | ||
| EP15184192 | 2015-09-08 | ||
| PCT/EP2015/074269 WO2016062720A1 (en) | 2014-10-22 | 2015-10-20 | Modified virus-like particles of cmv |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017538672A JP2017538672A (ja) | 2017-12-28 |
| JP2017538672A5 true JP2017538672A5 (https=) | 2018-11-22 |
| JP6942313B2 JP6942313B2 (ja) | 2021-09-29 |
Family
ID=54337283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017522532A Active JP6942313B2 (ja) | 2014-10-22 | 2015-10-20 | Ｃｍｖ由来改変ウイルス様粒子 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10532107B2 (https=) |
| EP (1) | EP3209326A1 (https=) |
| JP (1) | JP6942313B2 (https=) |
| KR (2) | KR20250034187A (https=) |
| CN (2) | CN114685626B (https=) |
| AU (1) | AU2015335027B2 (https=) |
| CA (1) | CA2963709A1 (https=) |
| CL (1) | CL2017000987A1 (https=) |
| CO (1) | CO2017004119A2 (https=) |
| IL (1) | IL251532B (https=) |
| MA (1) | MA40824A (https=) |
| MX (1) | MX387985B (https=) |
| MY (1) | MY187462A (https=) |
| NZ (1) | NZ731205A (https=) |
| PE (1) | PE20171133A1 (https=) |
| PH (1) | PH12017500727A1 (https=) |
| RU (1) | RU2706970C2 (https=) |
| SG (2) | SG10201903538YA (https=) |
| TN (1) | TN2017000133A1 (https=) |
| WO (1) | WO2016062720A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA40824A (fr) | 2014-10-22 | 2017-08-29 | Saiba Gmbh | Particules de cmv de type virus modifié |
| WO2017179025A1 (en) | 2016-04-15 | 2017-10-19 | Alk-Abelló A/S | Epitope polypeptides of ragweed pollen allergens |
| WO2017186808A1 (en) * | 2016-04-27 | 2017-11-02 | Allergy Therapeutics (Uk) Limited | Treatment of peanut allergy |
| BR112018071965A2 (pt) * | 2016-04-27 | 2019-03-06 | Benchmark Animal Health Ltd | tratamento da dermatite atópica canina |
| WO2018162577A1 (en) | 2017-03-07 | 2018-09-13 | Universität Zürich | Treatment of pruritus in horses |
| MX2020006105A (es) * | 2017-12-11 | 2020-11-09 | Ubi Ip Holdings | Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica. |
| US11433139B2 (en) * | 2018-03-16 | 2022-09-06 | Zoetis Services Llc | Peptide vaccines against interleukin-31 |
| AU2019253193B2 (en) | 2018-04-10 | 2026-02-05 | Ac Immune Sa | Anti-abeta therapeutic vaccines |
| US20210205425A1 (en) | 2018-05-28 | 2021-07-08 | Evax Ag | Treatment of urticaria |
| JP7623282B2 (ja) * | 2018-12-20 | 2025-01-28 | サイバ アクチェンゲゼルシャフト | 融合によって修飾されたｃｍｖのウイルス様粒子 |
| US20220073582A1 (en) * | 2018-12-31 | 2022-03-10 | United Neuroscience Limited | Peptide immunogens targeting calcitonin gene-related peptide (cgrp) and formulations thereof for prevention and treatment of migraine |
| WO2021083766A1 (en) | 2019-10-29 | 2021-05-06 | Evax Ag | Treatment of pruritus in horses |
| US20230038487A1 (en) * | 2019-11-25 | 2023-02-09 | The Regents Of The University Of California | Modified viral therapeutics and uses thereof |
| WO2021260131A1 (en) | 2020-06-25 | 2021-12-30 | Saiba AG | Virus-like particles of cmv modified by fusion |
| AU2021378075B2 (en) * | 2020-11-11 | 2025-03-27 | Borea Therapeutics S.R.L. | Modified viral particles for gene therapy |
| WO2022109403A1 (en) * | 2020-11-23 | 2022-05-27 | Scout Bio, Inc. | Antigen-binding molecules and uses thereof |
| CN117534736A (zh) * | 2020-12-15 | 2024-02-09 | 深圳赫兹生命科学技术有限公司 | 一种用于生产vlp重组疫苗的cmv病毒样颗粒及其制备方法 |
| CN118647399A (zh) | 2022-01-19 | 2024-09-13 | 伯尔尼大学 | 病毒样颗粒和微晶酪氨酸的组合物 |
| CN114437211B (zh) * | 2022-01-26 | 2024-03-12 | 南京麦西崴克生物科技有限公司 | 基于猫过敏原Fel d1的卵黄抗体的制备方法 |
| JP2025507875A (ja) | 2022-02-28 | 2025-03-21 | トライデム バイオサイエンス ゲーエムベーハー ウント コンパニー カーゲー | 少なくともβ－グルカン若しくはマンナンからなるか、又はこれを含む結合体 |
| EP4486389A1 (en) | 2022-02-28 | 2025-01-08 | Tridem Bioscience GmbH & Co KG | A conjugate comprising at least a beta-glucan |
| CA3266002A1 (en) | 2022-08-30 | 2024-03-07 | Saiba Animal Health Ag | Veterinary compositions of modified virus-like particles of cmv and ngf antigens |
| CN118684781A (zh) * | 2023-03-21 | 2024-09-24 | 深圳赫兹生命科学技术有限公司 | GnRH-VLP重组去势疫苗及其制备方法 |
| GB202400747D0 (en) * | 2024-01-19 | 2024-03-06 | Univ Dundee | IL31-VLP and medical uses thereof |
| US20250281584A1 (en) | 2024-03-04 | 2025-09-11 | Boehringer Ingelheim Vetmedica Gmbh | Active vaccination for the treatment of ngf-related disorders |
| WO2025186317A1 (en) | 2024-03-06 | 2025-09-12 | Elanco Us Inc. | Veterinary compositions of modified virus-like particles of cmv and canine il-1beta mutein antigens |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6419931B1 (en) * | 1991-08-26 | 2002-07-16 | Epimmune Inc. | Compositions and methods for eliciting CTL immunity |
| WO1999066950A1 (en) * | 1998-06-20 | 1999-12-29 | United Biomedical Inc. | Synthetic somatostatin immunogen for growth promotion in farm animals |
| CA2407897A1 (en) * | 2000-05-05 | 2001-11-15 | Cytos Biotechnology Ag | Molecular antigen arrays and vaccines |
| AU7658101A (en) * | 2000-07-28 | 2002-02-13 | Cytos Biotechnology Ag | Compositions for inducing self-specific anti-ige antibodies and uses thereof |
| AU2002363382B2 (en) | 2001-11-07 | 2007-07-19 | Cytos Biotechnology Ag | Antigen arrays presenting IL-5, IL-3 or eotaxin for treatment of allergic eosinophilic diseases |
| MXPA04003901A (es) * | 2001-11-07 | 2004-07-08 | Cytos Biotechnology Ag | Disposiciones de antigenos para el tratamiento de enfermedades eosinofilicas alergicas. |
| JP2006507800A (ja) | 2002-06-07 | 2006-03-09 | ラージ・スケール・バイオロジー・コーポレイション | 可撓性ワクチンアセンブリおよびワクチン送達プラットフォーム |
| US7138252B2 (en) | 2002-07-17 | 2006-11-21 | Cytos Biotechnology Ag | Molecular antigen arrays |
| GB0228715D0 (en) * | 2002-12-09 | 2003-01-15 | Glaxosmithkline Biolog Sa | Vaccine |
| RU2375076C2 (ru) | 2003-07-10 | 2009-12-10 | Цитос Биотехнологи Аг | Укомплектованные вирусоподобные частицы |
| WO2005091753A2 (en) | 2004-03-25 | 2005-10-06 | Large Scale Biology Corporation | Flexible vaccine assembly and vaccine delivery platform |
| WO2005100995A2 (en) | 2004-04-06 | 2005-10-27 | Mount Sinai School Of Medicine | Methods of determining allergen response using microarray imminoassay techinques |
| MX2007003171A (es) * | 2004-09-21 | 2007-05-23 | Cytos Biotechnology Ag | Particulas tipo virus que comprenden una proteina de fusion de la proteina de cubierta de ap205 y un polipeptido antigenico. |
| WO2006088955A2 (en) * | 2005-02-14 | 2006-08-24 | Zymogenetics, Inc. | Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells |
| ZA200707413B (en) * | 2005-03-18 | 2009-01-28 | Cytos Biotechnology Ag | Cat allergen fusion proteins and uses thereof |
| CA2636139A1 (en) * | 2005-12-14 | 2007-06-21 | Cytos Biotechnology Ag | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
| WO2007113633A2 (en) | 2006-04-03 | 2007-10-11 | Pfizer Products Inc. | Immunogenic compositions comprising cat allergen fel dl |
| EP2140880B1 (en) | 2008-07-04 | 2012-11-14 | HAL Allergy Holding B.V. | Modification of allergens |
| CA2798739A1 (en) * | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Nanocarrier compositions with uncoupled adjuvant |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| HUP1100470A2 (en) * | 2011-08-30 | 2013-03-28 | Mezoegazdasagi Biotechnologiai Kutatokoezpont | Nanoparticle-based veterinary vaccine |
| CN102943087A (zh) * | 2012-11-26 | 2013-02-27 | 中国农业科学院上海兽医研究所 | 兔出血症病毒新型亚单位疫苗及其制备方法 |
| US10050902B2 (en) | 2013-10-28 | 2018-08-14 | Hitachi, Ltd. | Methods and apparatus for de-duplication and host based QoS in tiered storage system |
| MA40824A (fr) | 2014-10-22 | 2017-08-29 | Saiba Gmbh | Particules de cmv de type virus modifié |
| JP6987744B2 (ja) * | 2015-09-08 | 2022-01-05 | ウニヴェルズィテート チューリッヒ | 虫刺され過敏症の治療 |
| HK1255206A1 (zh) | 2015-09-08 | 2019-08-09 | 苏黎世大学 | 抗猫过敏的组合物 |
| WO2017186808A1 (en) | 2016-04-27 | 2017-11-02 | Allergy Therapeutics (Uk) Limited | Treatment of peanut allergy |
| BR112018071965A2 (pt) | 2016-04-27 | 2019-03-06 | Benchmark Animal Health Ltd | tratamento da dermatite atópica canina |
| JP7623282B2 (ja) | 2018-12-20 | 2025-01-28 | サイバ アクチェンゲゼルシャフト | 融合によって修飾されたｃｍｖのウイルス様粒子 |
-
2015
- 2015-10-19 MA MA040824A patent/MA40824A/fr unknown
- 2015-10-20 SG SG10201903538YA patent/SG10201903538YA/en unknown
- 2015-10-20 CA CA2963709A patent/CA2963709A1/en active Pending
- 2015-10-20 CN CN202210351341.8A patent/CN114685626B/zh active Active
- 2015-10-20 SG SG11201703083QA patent/SG11201703083QA/en unknown
- 2015-10-20 TN TN2017000133A patent/TN2017000133A1/en unknown
- 2015-10-20 KR KR1020257006196A patent/KR20250034187A/ko active Pending
- 2015-10-20 WO PCT/EP2015/074269 patent/WO2016062720A1/en not_active Ceased
- 2015-10-20 CN CN201580064884.XA patent/CN108064276B/zh active Active
- 2015-10-20 EP EP15781949.1A patent/EP3209326A1/en active Pending
- 2015-10-20 AU AU2015335027A patent/AU2015335027B2/en active Active
- 2015-10-20 PE PE2017000737A patent/PE20171133A1/es unknown
- 2015-10-20 MX MX2017005242A patent/MX387985B/es unknown
- 2015-10-20 KR KR1020177013820A patent/KR102775741B1/ko active Active
- 2015-10-20 JP JP2017522532A patent/JP6942313B2/ja active Active
- 2015-10-20 NZ NZ731205A patent/NZ731205A/en unknown
- 2015-10-20 RU RU2017111266A patent/RU2706970C2/ru active
- 2015-10-20 MY MYPI2017701368A patent/MY187462A/en unknown
- 2015-10-20 US US15/520,676 patent/US10532107B2/en active Active
-
2017
- 2017-04-03 IL IL251532A patent/IL251532B/en active IP Right Grant
- 2017-04-20 CL CL2017000987A patent/CL2017000987A1/es unknown
- 2017-04-20 PH PH12017500727A patent/PH12017500727A1/en unknown
- 2017-04-27 CO CONC2017/0004119A patent/CO2017004119A2/es unknown
-
2019
- 2019-11-26 US US16/696,161 patent/US11324836B2/en active Active
-
2022
- 2022-04-06 US US17/714,307 patent/US12605454B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017538672A5 (https=) | ||
| Balke et al. | Recent advances in the use of plant virus-like particles as vaccines | |
| RU2017111266A (ru) | Модифицированные вирусоподобные частицы вируса мозаики огурца | |
| RU2486206C2 (ru) | Гипоаллергенный слитый белок, молекула нуклеиновой кислоты, кодирующая его, вектор экспрессии, клетка-хозяин, вакцинная композиция и его применение | |
| Deng et al. | Protein nanoparticle vaccine based on flagellin carrier fused to influenza conserved epitopes confers full protection against influenza A virus challenge | |
| JP2014530010A5 (https=) | ||
| JP2006504653A5 (https=) | ||
| HRP20171213T1 (hr) | Glikoproteinske čestice nalik virusu (vlp) bjesnoće | |
| JP2015501840A5 (https=) | ||
| Shim et al. | Sublingual delivery of vaccines for the induction of mucosal immunity | |
| JP2010516290A5 (https=) | ||
| JP2011250797A5 (https=) | ||
| JP2012501959A5 (https=) | ||
| EA202090738A1 (ru) | Способ безопасного индуцирования иммунитета против rsv | |
| JP2019506175A5 (https=) | ||
| JP2024504566A (ja) | 核酸ワクチン | |
| JP2023518340A5 (https=) | ||
| JP2016511747A5 (https=) | ||
| TW202202169A (zh) | 預防嚴重急性呼吸症候群冠狀病毒第二型（ｓａｒｓ－ｃｏｖ－２）感染的生物可降解奈米複合物疫苗及方法 | |
| JP2010506926A5 (https=) | ||
| JP2015529677A5 (https=) | ||
| Pan et al. | A double-blind, randomized controlled trial to evaluate the safety and immunogenicity of an intranasally administered trivalent inactivated influenza vaccine with the adjuvant LTh (αK): A phase II study | |
| Nagpal et al. | Current clinical status of new COVID-19 vaccines and immunotherapy | |
| Mansoor et al. | Intranasal delivery of nanoparticles encapsulating BPI3V proteins induces an early humoral immune response in mice | |
| Nie et al. | Self-adjuvant multiepitope nanovaccine based on ferritin induced long-lasting and effective mucosal immunity against H3N2 and H1N1 viruses in mice |